Two hours after start of therapy, a strong decrease in BrdU-positive cells was detected in both p53+/+ and E177R leukemias, attesting to the known ability of E177R in mounting a cell cycle arrest [30], whereas p53-null leukemia retained high levels of proliferation (Fig. 7A). Here, TP53 is linked to leukemia.